Release of more study results

Panion Animal Health AB develops a new gene therapy treatment for epilepsy in dogs. The clinical phase of a safety study in dogs under the lead of associate professor David Woldbye at the University of Copenhagen was recently finalized, as reported on August 30, 2018.

More study results are now available from the blood samples of the dogs, specifically relating to the presence of the vector in the time after treatment. The testing was performed in a professional GLP testing facility in Germany with very high quality and using updated, sensitive methods.

"The results confirm our expectations and the sampling period was in the right time frame" says Anja Holm, CEO of Panion. "We find that this part of the study is successful and of good quality. It is also an important and reassuring result, that there was no spread of vector between the dogs, i.e. from treated to control dogs in contact, at the levels tested in this study model. This builds part of the picture for a new gene therapy treatment and we will discuss the results with the authorities. It is necessary to get a good indication of the overall registration requirements in the light of our data, before we can finalize the development plan for our intended new product."

Panion Animal Health AB will meet with the US authorities in the FDA Presubmission meeting in October 2018. More information will be released about additional study results as the analyses will be finalized and reported in the coming months.

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion's CEO, Anja E. H. Holm, for publication on September 21 2018.

2018-09-21

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer


Panion starts clinical study in dogs

Panion Animal Health AB develops a novel gene therapy treatment for dogs with epilepsy. The first clinical trial will be conducted at Long Island Veterinary Specialists, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC ("LIVS") in New York, USA. It is a pilot study to evaluate the efficacy of the treatment in patient dogs with idiopathic epilepsy. It is the first time that the gene therapy treatment is made available for client-owned family dogs.


Invitation to investor meeting in Stockholm, Friday 14th of December 2018, 12-13

Panion Animal Health AB invites all interested persons to an investor meeting at Mangolds offices, Engelbrektsplan 2, Stockholm on Friday the 14th of December 2018 from 12 - 13.


Final dog study results


Memorandum publicerat

Investeringsmemorandum - Styrelsen för Panion Animal Health AB (publ) publicerar inbjudan att teckna aktier i Bolaget.

Teckningsperiod: 7 december 2018 - 21 december 2018

Teckningskurs: 1 SEK per aktie.



Panion Animal Health AB genomför företrädesemission om cirka 7,7 MSEK

Panion meddelar idag att styrelsen i Panion Animal Health AB ("Panion" eller "Bolaget") den 28 november 2018, med stöd av bemyndigande lämnat vid årsstämman den 29 maj 2018, beslutat att genomföra en nyemission av 7 687 374 aktier med företrädesrätt för befintliga aktieägare. Teckningskursen i nyemissionen är 1 krona vilket vid full teckning kommer att tillföra bolaget cirka 7,7 Mkr före emissionskostnader om cirka 0,2 Mkr.


Article in Animal Pharm nov 23

Panion targets gene therapy pilot study in North America


2018 Q3 report, Period July-September for Panion Animal Health AB

Period July-September

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -536 (-923).
  • Earnings per share: SEK -0,03 (-0,25).
  • Liquidity at the end of the period: kSEK 1 987 (1 166).

Period January-September

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -2 532 (-3 501).
  • Earnings per share: SEK -0,03 (-0,25).
  • Liquidity at the end of the period: kSEK 1 987 (1 166).


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: